COMPASS Pathways appoints Kabir Nath as CEO

Appointments

COMPASS Pathways has announced the appointment of Kabir Nath as CEO as of 1 August. Kabir brings decades of experience in the healthcare industry into his new role.

COMPASS is a mental health care company dedicated to accelerating patient access to evidencebased innovation in mental health. In is role, Kabir will continue building on COMPASS’ success and work advancing patient access to evidence-based, technology-enabled innovative care models, combining pharmacological, psychological, and digital solutions.

George Goldsmith, current CEO and Chairman of COMPASS Pathways, said: “We founded COMPASS Pathways to transform mental health care by creating a personalised, predictive and preventative model of care. As we enter the next stage of development, Kabir brings a track record of successful strategic growth, and a deep dedication to this mission.

“Working alongside our talented leadership team, he will leverage his extensive background in leading the commercialisation of innovative therapies to bring COMP360 psilocybin therapy to the large number of patients who are not currently being helped by existing treatments.”

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

The biotechnology company foghorn therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be replacing Sam Agresta after his retirement on 11 September 2023.

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed professor Josef Penninger as scientific director.

Olav Hellebø to join Cytovation’s board of directors

Cytovation, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

Olav Hellebø to join Cytovation’s board of directors

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Simon Sinclair appointed as chief medical officer of Ondine Biomedical

Pharmafocus

Categories

Social Footprints